The global sarcoma drugs market size is projected to expand at a significant CAGR during the forecast period, 2021-2028. The growth of the market is attributed to increase in the incidence of soft tissue sarcoma (STS), a rapid increase in the adoption of novel drugs, and the presence of set of automated processes to build and deploy the drugs effectively and efficiently.
Sarcoma refers to a type of cancer that takes place in bone or soft tissues of the body such as fibrous tissue, blood vessels, cartilage, muscle, fat, or other connective tissues. Different types of cancer are present due to the presence of different types of sarcoma. For instance, sarcoma in fats is known as liposarcoma, sarcoma in bone is known as osteosarcoma, and sarcoma in muscle is known as rhabdomyosarcoma. Sarcoma is anticipated to grow both in children and in adults and its treatment is based on the grade and type of cancer. The treatment of this type of cancer is depended upon how the cancer cell looks like when observed under a microscope and how speedily they are expected to grow and spread. It is reported that two-three people out of 100,000 are diagnosed with soft tissue sarcoma (STS) globally on an annual basis.
According to a report based on the US, 12,715 individuals were diagnosed with soft tissue sarcoma (STS) among which 5,070 death took place in 2017. Nearly 3,373 osteosarcoma cases (sarcoma in bones) were reported among which 1,649 deaths reported. The risk to develop sarcoma is 0.4% in a lifetime and in the age group but 45% of people between the age group of 0-35 years are likely to develop with osteosarcoma (sarcoma in bones) and 21% of soft tissue sarcoma (STS) are diagnosed. The only approved therapy or treatments available at present are chemotherapy and targeted therapy. Yondelis and Halaven, are two drugs developed by Johnson & Johnson and Eisai respectively for the effective treatment of cancer. Evolution in multiple phase I/II trials is done by checkpoint inhibitors (PD-1/PD-L1). Effective and safer treatment options are provided to patients when these methods are combined with standard therapies. Presently 12 out of 45 drugs are in the process of development that can be used for the treatment of osteosarcoma (bone sarcoma) and soft tissue sarcoma (STS). Several other antibodies are also under development in phase I and phase II trials.
Key Players Covered in the Report
Novartis; Eli Lilly, Amgen; Pfizer; Johnson & Johnson; Eisai; Bayer; ytRx; Tracon Pharma; Blueprint Medicines; Arog Pharmaceuticals; Advenchen Laboratories; and Karyopharm Therapeutics
Market Segment Insights
On the basis of treatment types, the global sarcoma drugs market is bifurcated into chemotherapy and targeted therapy. With the introduction of targeted therapies, the market for treatment for sarcoma has immensely changed over the past few years. However, the chemotherapy segment is anticipated to dominate the market in the coming years owing to the fact that chemotherapy is highly adopted as a primary treatment procedures. It works throughout the whole body by damaging the cancer cells not only in the place where it originated but also in the place where it spreads. This fact makes chemotherapy to be the primary method for the treatment of sarcoma. The other therapies or surgery helps to remove the cancer cell or kill it at a particular place.
Get Sample Report @ Request For Sample of Sarcoma Drugs Market – Global Industry Analysis, Growth, Share, Size, Trends, and Forecast | Growth Market Reports
In terms of regions, the global sarcoma drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North held a key share of the market and the trend is expected to continue in the coming years owing to the wide prevalence of cancer patients and high research activities for development of innovative drugs for the treatment in the region. Moreover, the presence of the key manufacturers especially in the US and rise in adoption of novel therapies for the treatment play key roles for the regional market growth. Additionally, several activities have been undertaken for the development of therapies that are patient-to-patient customized by key pharmaceutical players in the region.
About Growth Market Reports:
Growth Market Reports provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Industry Intelligence Solutions”. Growth Market Reports has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys.
Contact:
Growth Market Reports
Phone: +1 909 414 1393
Email: sales@growthmarketreports.com
Web: https://growthmarketreports.com
Follow Us: LinkedIn | Twitter
0
